Meridian Bioscience

Meridian Bioscience Announces FDA Submission for New Curian® Campy Assay

Retrieved on: 
Thursday, April 1, 2021
Chemistry, Physical sciences, Natural sciences, Laboratory techniques, Meridian Bioscience, Immunologic tests, Epsilonproteobacteria, Assay, Lateral flow test, Campylobacter

CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Companys new Curian Campy assay.

Key Points: 
  • CINCINNATI, April 01, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a leading global provider of diagnostic testing solutions and life science raw materials, today announced that it has made a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the Companys new Curian Campy assay.
  • This assay is one of many assays in the pipeline that expands the Curian menu, continuing Meridians leadership in the gastrointestinal disease and lateral flow testing market.
  • Curian Campy, for use with the Curian Analyzer, is a rapid, qualitative fluorescent immunoassay for the detection of Campylobacter spp.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Meridian Bioscience to Participate in H.C. Wainwright Global Life Sciences 2021 Virtual Conference

Retrieved on: 
Thursday, March 4, 2021
Meridian Bioscience

CINCINNATI, March 04, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference.

Key Points: 
  • CINCINNATI, March 04, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference.
  • Jack Kenny, Chief Executive Officer, will pre-record a presentation that will be available on March 9, 2021.
  • For additional information on the H.C. Wainwright Global Life Sciences 2021 Virtual Conference, please visit www.hcwevents.com/globalconference/ .
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission

Retrieved on: 
Tuesday, February 23, 2021
Meridian Bioscience, Food and Drug Administration, Principal meridian

Following the submission of Meridians written response to the FDAs request for additional information on its Revogene SARS-CoV-2 test on February 16, 2021 and further discussions with the FDA, on February 22, 2021, Meridian Bioscience elected to withdraw its EUA application.

Key Points: 
  • Following the submission of Meridians written response to the FDAs request for additional information on its Revogene SARS-CoV-2 test on February 16, 2021 and further discussions with the FDA, on February 22, 2021, Meridian Bioscience elected to withdraw its EUA application.
  • Upon notification to the FDA of its intent to re-submit an EUA application, during its third fiscal quarter, Meridian expects to resume shipping of this test to customers.
  • The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown

Retrieved on: 
Wednesday, February 3, 2021
Meridian Bioscience, Meridian, Redi, Newtown, Connecticut

The funding will help Meridian expand production of Revogene test kits in the Quebec City facility and build a new semi-automated, state-of-the-art, two-line production facility near the corporate headquarters in the Village of Newtown (Cincinnati, OH).

Key Points: 
  • The funding will help Meridian expand production of Revogene test kits in the Quebec City facility and build a new semi-automated, state-of-the-art, two-line production facility near the corporate headquarters in the Village of Newtown (Cincinnati, OH).
  • NIH launched the RADxSM initiative to speed innovation in developing, commercializing, and implementing technologies for COVID-19 testing.
  • JobsOhio and REDI Cincinnati are partnering with Meridian to support its growth on the Meridian Bioscience campus in Newtown, Ohio.
  • The Village of Newtown has also provided support to the project through tax abatements applied to the buildoutof the newly leased facility.

Meridian Bioscience to Hold First Quarter Fiscal 2021 Financial Results Conference Call on February 5, 2021

Retrieved on: 
Wednesday, January 13, 2021
Meridian Bioscience, Medical diagnosis

CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021.

Key Points: 
  • CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021.
  • Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.
  • Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing.

Meridian Bioscience Announces Better-than-expected Preliminary First Quarter Fiscal 2021 Revenue Results

Retrieved on: 
Thursday, January 7, 2021
Meridian Bioscience, fis, Companies, Service companies, Economy of the United States

CINCINNATI, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021.

Key Points: 
  • CINCINNATI, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced preliminary financial results for the first quarter of fiscal 2021.
  • The Company expects first quarter of fiscal 2021 revenue to be approximately $92 million, compared to $47.4 million in the first quarter of fiscal 2020, reflecting an increase of approximately 94%.
  • Diagnostics segment revenue is expected to be roughly flat compared to the fourth quarter of fiscal 2020, with revenue of approximately $30 million.
  • The full financial results and any changes to fiscal 2021 guidance will be discussed on our first quarter earnings call, currently scheduled for Friday, February 5, 2021.

Meridian Bioscience to Participate in H. C. Wainright Bioconnect 2021 Virtual Conference

Retrieved on: 
Wednesday, January 6, 2021
Meridian Bioscience, Frank Wainright

CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference.

Key Points: 
  • CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference.
  • Jack Kenny, Chief Executive Officer, will pre-record a fireside chat that will be available on January 11, 2021.
  • Jack Kenny will also be participating in a panel discussion hosted by former FDA Commissioner Scott Gottlieb, M.D.
  • For additional information on the H. C. Wainright Bioconnect 2021 Virtual Conference, please visit www.h c w events.com/bioconnect .

Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

Retrieved on: 
Thursday, December 3, 2020
Meridian Bioscience, Meridià, Freeze-drying, Companies, Matter

While molecular diagnostic tests are progressively moving towards a dried-down format, there are technical challenges in developing lyophilization-compatible mixes that require lengthy optimization and expensive lyophilization equipment.

Key Points: 
  • While molecular diagnostic tests are progressively moving towards a dried-down format, there are technical challenges in developing lyophilization-compatible mixes that require lengthy optimization and expensive lyophilization equipment.
  • Meridian is committed to suppling innovative solutions to the diagnostic industry to simplify and accelerate development of superior diagnostic assays.
  • For more information on partnering with Meridian Bioscience, please visit meridianlifescienc e .com or email lourdes.weltzien@meridia n lifescience.com .
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Meridian Bioscience Participates in Piper Sandler 32nd Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 23, 2020
Meridian Bioscience, Meridian, Mississippi, Geography of Mississippi, Cities in the United States

CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Key Points: 
  • CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
  • Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer pre-recorded a fireside chat on Tuesday, November 17, 2020.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.
  • Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing.

Meridian Bioscience to Participate in Canaccord Genuity Virtual MedTech & Diagnostics Forum

Retrieved on: 
Monday, November 16, 2020
Canaccord Genuity, Finance, Meridian Bioscience, Genuity, Meridian, Mississippi, NASDAQ, Service companies, Companies

CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET.

Key Points: 
  • CINCINNATI, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a live stream fireside chat at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020 at 12:30pm ET.
  • To access the live stream, go to the Events & Presentations section of the Companys Investor Relations website at https://investor.meridianbioscience.com/ .
  • Participants should register several minutes in advance of the events start time by following the link provided for the event.
  • Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.